Results 201 to 210 of about 30,178 (280)

MHC-I Upregulation and Increased Glucose Dependence Define Innate Antifungal Immune Responses to Cryptococcus neoformans. [PDF]

J Infect Dis
Nair AS, Wozniak KL.
europepmc   +1 more source

In Vivo Immunoscoring Technique to Monitor Anti‐CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer

Cancer Medicine, Volume 15, Issue 10, October 2026.
Intravital imaging using MCP1‐FITC and dextran‐AF680 assesses macrophage targeting and polarization in murine 4T1 tumor models. Visualization of M1‐like and M2‐like macrophages and M1/M2 ratio quantification support evaluation of anti‐CD47 immunotherapy, highlighting the potential of macrophage‐targeted imaging for patient stratification and treatment ...
Minfeng Yang, Shiqiang Hou, Chi Ming Wong, Hongzhao Chen, Chunjin Jin, Song‐Bai Liu, Jung Sun Yoo   +6 more
wiley   +1 more source

Photodynamic priming enhances anti-PD1 therapy responses in patient-derived pancreatic cancer organoid immune cocultures. [PDF]

Front Immunol
De Silva P, Wekking D, Choe JJ, Kidd MD, Pearce JL, Rocha Castellanos DM, Zelga P, Jenkins R, Wang KK, Chandrasekhara V, Maytin EV, Liss AS, Hasan T.   +12 more
europepmc   +1 more source

Production of the High Value Pharmaceutical Target, Human Granulocyte‐Colony Stimulating Factor, in Nicotiana benthamiana Is Improved by Co‐Expression of the Transcriptional Regulator of the Unfolded Protein Response, bZIP60

Plant Biotechnology Journal, EarlyView.
Nazgul Wagner, Konstantin Musiychuk, Stephen Tottey, Jukka Kervinen, Hong Bi, Stephen J. Streatfield, Rainer Fischer, Vidadi Yusibov   +7 more
wiley   +1 more source

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background This clinical trial sought to determine whether SL‐172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher‐risk myelodysplastic syndrome (HR‐MDS) or acute myeloid leukemia (AML). Methods Dose escalation: doses of 1, 3, and 6 mg/kg SL‐172154 was evaluated as monotherapy or in combination ...
Naval G. Daver, Amer M. Zeidan, Anthony S. Stein, Joshua F. Zeidner, Keri Maher, Emily Curran, Dale Bixby, Wanxing Chai‐Ho, Maximilian Stahl, Karen W. L. Yee, Don Stevens, Sawa Ito, Jana Reynolds, Patrick Medd, Emma Searle, Andrew Sochacki, Mary Lynn Savoie, Steven Green, Kazunobu Kato, Robert Hernandez, Simon Metenou, Bo Ma, Lini Pandite, Taylor H. Schreiber, David A. Sallman   +24 more
wiley   +1 more source

Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Bioactive peptides (BAPs) derived from host, marine, insect, plant and synthetic sources share cationic, amphipathic structures adopting α‐helical, β‐sheet or cyclic conformations. These features underlie anti‐cancer effects, including membrane disruption, apoptosis and cell‐cycle arrest, anti‐metastatic activity, reduced invasion and migration, and ...
Najwa Doha, Richa Gill, Sergio Crovella, Haissam Abou‐Saleh, Sahar Isa Da'as   +4 more
wiley   +1 more source

Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. [PDF]

Cell Rep Med
Olson DJ, Liu BA, Younan P, Blahnik-Fagan G, Stacey RG, Gosink J, Snead K, Tenn E, Hensley K, Sahetya D, Nesterova A, Zaval M, Cao A, O'Day C, Heiser RA, Lewis TS, Gardai SJ, Nakazawa T, Shimazaki M, Carosino C, Szeto GL, Sandall S.   +21 more
europepmc   +1 more source

Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia

The Journal of Clinical Pharmacology, Volume 66, Issue 10, October 2026.
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Albert Qin, Lucia Masarova, Haoqi Chen, Zhijian Xiao, Jie Jin, Harinder Gill, Brandi N Reeves, Firas El Chaer, Keita Kirito, Norio Komatsu, Ghaith Abu‐Zeinah, Kazuya Shimoda, Oleh Zagrijtschuk, Toshiaki Sato, Daoxiang Wu, Lei Wu, Xia Su, Yucheng Gao, Jie Cui, Lei Zhang, Ruben A Mesa   +20 more
wiley   +1 more source

Determinants of C₁₆-Ceramide Binding to p53. [PDF]

Biomolecules
Childress MS, Jeffries KA, Krupenko SA, Krupenko NI.   +3 more
europepmc   +1 more source

Tripterine Liposome Exerts Antitumor and Immunomodulatory Effects in Pancreatic Ductal Adenocarcinoma

MedComm, Volume 7, Issue 10, October 2026.
Tripterine liposome (TP‐lipo) exerts anti‐pancreatic ductal adenocarcinoma (PDAC) effects through direct suppression of tumor cells and modulation of the tumor microenvironment (TME). TP‐lipo induces apoptosis and inhibits the clonogenicity, migration, and invasion of KPC cells in vitro.
Lirui Tang, Yi Lin, Xueqin Jiang, Xiaohe Tian, Giuseppe Battaglia, Yuquan Wei, Wenshuang Wu, Xuemei He, Xiawei Wei   +8 more
wiley   +1 more source